Nkarta, Inc. (NKTX)
| Market Cap | 196.76M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -104.08M |
| Shares Out | 71.29M |
| EPS (ttm) | -1.41 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 484,858 |
| Open | 2.830 |
| Previous Close | 2.830 |
| Day's Range | 2.760 - 2.860 |
| 52-Week Range | 1.630 - 3.650 |
| Beta | 0.67 |
| Analysts | Strong Buy |
| Price Target | 11.33 (+310.51%) |
| Earnings Date | May 13, 2026 |
About NKTX
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The com... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for NKTX stock is "Strong Buy." The 12-month stock price target is $11.33, which is an increase of 310.51% from the latest price.
News
Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers
SOUTH SAN FRANCISCO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat au...
Nkarta Transcript: 25th Annual Needham Virtual Healthcare Conference
The conference highlighted a strategic pivot to autoimmune diseases using off-the-shelf CAR-NK cell therapy, with a favorable safety profile and expanding outpatient access. Multiple indications are under study, with a data update and narrowed focus expected later this year. Cash runway extends into 2029.
Nkarta to Participate in Needham Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to trea...
Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights
SOUTH SAN FRANCISCO, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat au...
Nkarta Transcript: Leerink Global Healthcare Conference 2026
The discussion highlighted a strategic pivot to autoimmune disease, focusing on CD19-targeted NK cell therapy with a strong safety profile and outpatient potential. Dose escalation and full lymphodepletion are central to achieving durable remissions, with upcoming data to guide indication selection and pivotal trial advancement.
Nkarta Transcript: TD Cowen 46th Annual Health Care Conference
The conference highlighted progress in allogeneic NK cell therapy for autoimmune diseases, emphasizing a robust safety profile, harmonized dosing with full lymphodepletion, and plans for major data updates this year. Financial runway extends to 2029, supporting continued development and focus on the most promising indications.
Nkarta to Participate in March Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat...
Nkarta Transcript: Evercore ISI 8th Annual HealthCONx Conference
Data readouts for the I&I program are delayed to next year to ensure robust results from the updated Flu/Cy regimen, which has improved enrollment and engagement. The trial now uses a basket design across five indications, with strong FDA support and a cash runway into 2029.
Nkarta to Participate in Evercore Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat...
Nkarta Transcript: TD Cowen Immunology and Inflammation Summit
NK cell therapies are demonstrating rapid, deep B cell depletion and promising safety in autoimmune diseases, with ongoing dose escalation and protocol improvements. Robust clinical data are expected next year, supported by strong FDA collaboration and increased trial accessibility.
Nkarta Transcript: Stifel 2025 Healthcare Conference
Phase I CAR-NK trials for autoimmune diseases are progressing, with streamlined enrollment and harmonized trial design accelerating data generation. Deep B-cell depletion is emphasized as key for durable responses, and the company is well-funded with runway into 2029.
Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights
Enrollment now underway in second dose-escalation cohort Deep B-cell depletion observed in all patients treated to date who received NKX019 with lymphodepletion using fludarabine and cyclophosphamide...
Nkarta to Participate in November Investor Conferences
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today a...
Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat...
Nkarta Transcript: H.C. Wainwright 27th Annual Global Investment Conference
The CARN-K cell therapy platform is advancing in multiple autoimmune indications, with trials designed for broad accessibility, improved safety, and practical dosing. Key updates on safety, efficacy, and optimal dosing are expected later this year, with strong financial runway into 2029.
Nkarta to Participate in a September Investor Conference
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today ...
Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights
SOUTH SAN FRANCISCO, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today r...
Nkarta Transcript: H.C. Wainwright “HCW@Home” Series
The event highlighted the shift to autoimmune indications with a focus on CAR NK cell therapy, emphasizing safety, scalability, and outpatient potential. Key clinical trials are underway, with initial data expected later this year and a strong financial position supporting continued development.
Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series
SOUTH SAN FRANCISCO, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today a...
Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus
SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat...
Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space
Nkarta Inc. NKTX on Wednesday reported a first-quarter loss of 43 cents per share, beating the consensus loss of 44 cents.
Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights
Enrollment open in investigator-sponsored trial (IST) of NKX019 in myasthenia gravis; Ntrust-1, Ntrust-2, and IST of NKX019 in systemic lupus erythematosus remain open to enrollment Ntrust-1 expanded ...
Nkarta Transcript: 24th Annual Needham Virtual Healthcare Conference
The conference highlighted the promise of allogeneic CAR-NK therapies for autoimmune diseases, emphasizing their safety, scalability, and outpatient potential. Regulatory and operational challenges persist, but a strong financial position supports continued development and upcoming data milestones.
Nkarta to Participate in an April Investor Conference
SOUTH SAN FRANCISCO, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its p...
Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday?
Nkarta, Inc. NKTX reported a fourth-quarter earnings report on Wednesday with a loss of 35 cents per share, beating the consensus of a loss of 41 cents.